Genome-scale CRISPR screens identify host factors that promote human coronavirus infection

• Published in: Genome medicine 2022-01, Vol.14 (1), p.10-18, Article 10
• Main Authors: Grodzki, Marco, Bluhm, Andrew P, Schaefer, Moritz, Tagmount, Abderrahmane, Russo, Max, Sobh, Amin, Rafiee, Roya, Vulpe, Chris D, Karst, Stephanie M, Norris, Michael H
• Format: Article
• Language: English
• Subjects: ACE2; Analysis; Angiotensin-converting enzyme 2; Animals; Antiviral agents; Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Cell cycle; Cell interactions; Cell lines; Chlorocebus aethiops; Clustered Regularly Interspaced Short Palindromic Repeats - genetics; Common cold; Coronaviruses; COVID-19; COVID-19 - pathology; COVID-19 - virology; COVID-19 Drug Treatment; COVID-19 vaccines; CRISPR; Drug development; Epidemics; Epithelial cells; Exoribonucleases - antagonists & inhibitors; Exoribonucleases - genetics; Exoribonucleases - metabolism; FDA approval; Gene Editing - methods; Genes; Genetic engineering; Genome, Viral; Genomes; Genomics; Health aspects; HEK293 Cells; Host-Pathogen Interactions - drug effects; Host-Pathogen Interactions - genetics; Humans; Infection; Infections; Life cycles; Microtubule-Associated Proteins - antagonists & inhibitors; Microtubule-Associated Proteins - genetics; Microtubule-Associated Proteins - metabolism; mRNA turnover; Pandemics; Plasmids; Proteins - antagonists & inhibitors; Proteins - genetics; Proteins - metabolism; Replication; Respiratory tract; RNA; RNA Interference; RNA, Guide, CRISPR-Cas Systems - metabolism; RNA, Small Interfering - metabolism; SARS-CoV-2 - drug effects; SARS-CoV-2 - genetics; SARS-CoV-2 - physiology; Severe acute respiratory syndrome coronavirus 2; Vaccines; Vero Cells; Viral infections; Virus Replication - genetics; Viruses
• ISSN: 1756-994X; 1756-994X
• DOI: 10.1186/s13073-022-01013-1

The COVID-19 pandemic has resulted in 275 million infections and 5.4 million deaths as of December 2021. While effective vaccines are being administered globally, there is still a great need for antiviral therapies as antigenically novel SARS-CoV-2 variants continue to emerge across the globe. Viruses require host factors at every step in their life cycle, representing a rich pool of candidate targets for antiviral drug design. To identify host factors that promote SARS-CoV-2 infection with potential for broad-spectrum activity across the coronavirus family, we performed genome-scale CRISPR knockout screens in two cell lines (Vero E6 and HEK293T ectopically expressing ACE2) with SARS-CoV-2 and the common cold-causing human coronavirus OC43. Gene knockdown, CRISPR knockout, and small molecule testing in Vero, HEK293, and human small airway epithelial cells were used to verify our findings. While we identified multiple genes and functional pathways that have been previously reported to promote human coronavirus replication, we also identified a substantial number of novel genes and pathways. The website https://sarscrisprscreens.epi.ufl.edu/ was created to allow visualization and comparison of SARS-CoV2 CRISPR screens in a uniformly analyzed way. Of note, host factors involved in cell cycle regulation were enriched in our screens as were several key components of the programmed mRNA decay pathway. The role of EDC4 and XRN1 in coronavirus replication in human small airway epithelial cells was verified. Finally, we identified novel candidate antiviral compounds targeting a number of factors revealed by our screens. Overall, our studies substantiate and expand the growing body of literature focused on understanding key human coronavirus-host cell interactions and exploit that knowledge for rational antiviral drug development.